WO2021041336A1 - Compositions d'anticorps igg et leurs procédés de fabrication - Google Patents

Compositions d'anticorps igg et leurs procédés de fabrication Download PDF

Info

Publication number
WO2021041336A1
WO2021041336A1 PCT/US2020/047675 US2020047675W WO2021041336A1 WO 2021041336 A1 WO2021041336 A1 WO 2021041336A1 US 2020047675 W US2020047675 W US 2020047675W WO 2021041336 A1 WO2021041336 A1 WO 2021041336A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
igg antibody
region
seq
igg
Prior art date
Application number
PCT/US2020/047675
Other languages
English (en)
Inventor
Michael A. Caligiuri
Hongsheng DAI
Tongwen ZHANG
Original Assignee
City Of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City Of Hope filed Critical City Of Hope
Priority to EP20858827.7A priority Critical patent/EP4017884A4/fr
Priority to CN202080070119.XA priority patent/CN114729058A/zh
Priority to US17/637,433 priority patent/US20220380457A1/en
Publication of WO2021041336A1 publication Critical patent/WO2021041336A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps, des protéines recombinantes et des procédés d'utilisation de ceux-ci comprenant, par exemple, des anticorps immunoglobuline G (IgG) et des protéines recombinantes comprenant une région Fab et une région Fc reliées par l'intermédiaire d'une région charnière, la région charnière étant résistante au clivage par une protéase. L'invention concerne également, entre autres, des anticorps immunoglobuline G (IgG) et des protéines recombinantes comprenant une région Fab et une région Fc reliées par l'intermédiaire d'une région charnière, et la région Fc ayant une affinité plus élevée pour un ligand par comparaison avec un Fc de type sauvage.
PCT/US2020/047675 2019-08-23 2020-08-24 Compositions d'anticorps igg et leurs procédés de fabrication WO2021041336A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP20858827.7A EP4017884A4 (fr) 2019-08-23 2020-08-24 Compositions d'anticorps igg et leurs procédés de fabrication
CN202080070119.XA CN114729058A (zh) 2019-08-23 2020-08-24 IgG抗体组合物和其制备方法
US17/637,433 US20220380457A1 (en) 2019-08-23 2020-08-24 Igg antibody compositions and methods of making the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962891200P 2019-08-23 2019-08-23
US62/891,200 2019-08-23

Publications (1)

Publication Number Publication Date
WO2021041336A1 true WO2021041336A1 (fr) 2021-03-04

Family

ID=74685762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/047675 WO2021041336A1 (fr) 2019-08-23 2020-08-24 Compositions d'anticorps igg et leurs procédés de fabrication

Country Status (4)

Country Link
US (1) US20220380457A1 (fr)
EP (1) EP4017884A4 (fr)
CN (1) CN114729058A (fr)
WO (1) WO2021041336A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109928A1 (fr) * 2021-12-16 2023-06-22 上海宝济药业有限公司 Variant fc digéré par une enzyme de dégradation de l'anti-immunoglobuline

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013000234A1 (fr) * 2011-06-28 2013-01-03 Huabo Biopharm Co., Ltd Nouvelle protéine de fusion recombinante bifonctionnelle et sa préparation et son utilisation
US20150139984A1 (en) * 2010-12-23 2015-05-21 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
WO2018049248A1 (fr) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Virus oncolytique équipé de molécules d'engagement bispécifiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1943332A4 (fr) * 2005-10-14 2011-04-13 Medimmune Inc Affichage cellulaire de libraires d'anticorps

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150139984A1 (en) * 2010-12-23 2015-05-21 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
WO2013000234A1 (fr) * 2011-06-28 2013-01-03 Huabo Biopharm Co., Ltd Nouvelle protéine de fusion recombinante bifonctionnelle et sa préparation et son utilisation
WO2018049248A1 (fr) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Virus oncolytique équipé de molécules d'engagement bispécifiques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GARY KOBS : "IdeZ Protease: A New Tool for the Characterization of Antibodies", 19 October 2015 (2015-10-19), pages 1 - 5, XP055901762, Retrieved from the Internet <URL:https://www.promegaconnections.com/idez-protease-a-new-tool-for-the-characterization-of-antibodies/> [retrieved on 20210107] *
KINDER, M ET AL.: "Engineered Protease-resistant Antibodies with Selectable Cell -killing Functions", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 43, 25 October 2013 (2013-10-25), pages 30843 - 30854, XP055165750, DOI: 10.1074/jbc.M113.486142 *
See also references of EP4017884A4 *
SUZUKI, S ET AL.: "Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance", SCIENCE REPORTS, vol. 8, no. 17253, 2018, pages 1 - 10, XP055776016, DOI: 10.1038/s41598-018-35489-y *
ZHOU, C ET AL.: "Development of a novel mammalian cell surface antibody display platform", MABS, vol. 2, no. 5, 2010, pages 508 - 518, XP009162612, DOI: 10.4161/mabs.2.5.12970 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109928A1 (fr) * 2021-12-16 2023-06-22 上海宝济药业有限公司 Variant fc digéré par une enzyme de dégradation de l'anti-immunoglobuline

Also Published As

Publication number Publication date
EP4017884A1 (fr) 2022-06-29
CN114729058A (zh) 2022-07-08
US20220380457A1 (en) 2022-12-01
EP4017884A4 (fr) 2024-01-17

Similar Documents

Publication Publication Date Title
US20210238291A1 (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US11891445B1 (en) Anti-B7-H3 antibody and use thereof
IL279683A (en) Substances bound to immunoglobulin receptors Fc fusion region
IL309265A (en) Extracellular vesicles containing agonist-STING
US11472882B2 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CN112601544A (zh) 人类抗cd47抗体及其用途
WO2018089508A2 (fr) Anticorps anti-cd47
KR20230031373A (ko) 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
IL250622B2 (en) Prepared sirp-alpha fusion proteins and pharmaceutical preparations containing them
CA2955947A1 (fr) Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispecifiques, anticorps anti-cd3 activables multispecifiques et procedes d&#39;utilisation de ces anticorps
IL309201A (en) Compounds with anticancer activity
Fisher et al. Generation and preclinical characterization of an antibody specific for SEMA4D
IL295729A (en) Bispecific engineered anti-2her proteins, preparations containing them and their uses
IL294207A (en) Cancer treatment
IL302592A (en) Anti-TIGIT antibodies and their uses
US20220380457A1 (en) Igg antibody compositions and methods of making the same
JP7476346B2 (ja) ヒト神経成長因子に対する抗体
US20180371089A1 (en) Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecific antibody and uses thereof in caner therapy
IL307533A (en) Anti-CCR8 antibodies
CN114539405A (zh) 抗tigit抗体或其抗原结合片段
IL294257A (en) The composition of engineered monoclonal antibodies that are resistant to immunosuppressive cancer factors and their use
CA3113306A1 (fr) Polypeptides tetrameres se liant a her2
US20230059181A1 (en) IgE Antibody with Fcgamma Receptor binding
IL309021A (en) Agents and methods for activation and targeting of immune effector cells
KR20240049829A (ko) 항-4-1bb 나노바디

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20858827

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020858827

Country of ref document: EP

Effective date: 20220323